Andrew Wakefield's website and response to Sunday Times/Channel 4 Dispatches Programme (MMR)

[Sheri Nakken]

Andrew Wakefield's website and response

http://www.mmrthequestions.com/ (GO TO WEBSITE FOR MORE INFO)
BOOKMARK for future reference
*******
MMR: The Questions is a new and developing website. It will be used to
present contributions from scientists, other professionals and parents who
believe that there is sufficient evidence to warrant further research into
the issue of whether exposure to measles-containing vaccine increases
subsequent risk of a range of developmental disorders and/or
gastro-intestinal problems

The purpose of the site will be to provide access to pertinent scientific
materials, links to other sites of interest and a forum for discussion of
relevant topics.

MMR: The Questions will also provide a means for scientists to respond in
the public domain to any perceived misrepresentations of their work, their
motivations and their professional integrity.

Please email questions, suggestions and contributions to:
info@mmrthequestions.com
*********
MMR: The Questions

Issues Raised by the Sunday Times and the Channel 4 Dispatches Programme
A statement by Dr Andrew Wakefield
The Sunday Times and the Dispatches programme of 18th November raise a
number of issues in relation to MMR, autism and events at the Royal Free
Hospital. Since many of the claims by journalist Brian Deer have been
demonstrably false and there in no objectivity in the manner of their
intended portrayal, I declined to participate in any way in the making of
the Dispatches programme. In addition, vulnerable parents have complained
of being "tricked" into participating in the programme. I was not invited
to comment on the Sunday Times article prior to its publication.
----------------------------------------------------------------------------
----
The claim appears to be that, whilst at the Royal Free Hospital, I was
developing a new vaccine to compete with MMR and that I conspired to
undermine confidence in MMR vaccine in order to promote this new vaccine,
and that this represented a conflict of interest. This is untrue. The facts
are that:
no vaccine or anything resembling a vaccine was ever designed, developed or
tested by me or by any of my colleagues at the Royal Free Hospital;
it has never been my aim or intention to design, produce or promote a
vaccine to compete with MMR;
my genuine concerns about the safety of MMR are wholly unrelated to any
desire or opportunity to develop a competing vaccine;
there was no conspiracy as insinuated by the Sunday Times article;
there was no conflict or interest, actual or perceived.
In contrast, it was our intention, at one stage, to conduct a formal
therapeutic clinical trial of a compound that might have the ability to
promote the body’s immune response to measles in order to assess the
effects of this therapy upon the disease in children with regressive autism
and bowel disease. This compound is known as Transfer Factor and whilst
there is a large scientific literature on this subject, the nature and
mechanism of action of Transfer Factors are largely unknown.

The Transfer Factor that was intended for use in the trial was to be
against measles virus. I have urged and continue to urge parents to have
their children vaccinated against measles using the current vaccines. This
would be in direct conflict with the intentions that are part of the claim
that I was developing a new vaccine to bring onto the market. Whether a
Transfer Factor could ever protect children against measles is entirely
speculative and is something that was never studied or pursued by me or any
of my colleagues.

The Channel 4 programme implies commercial aspirations for personal gain.
In fact, the aim of the patent was to generate funding for the research
programme and a new Centre for Gastroenterology at the Royal Free Hospital.
This can be substantiated by contemporaneous documentation.

The patent application was motivated by two main factors. First, it was
felt that there may be difficulty in raising traditional grant funding for
cutting edge, controversial work that was vulnerable by virtue of the fact
that it might conflict with perceived wisdom and the commercial interests
of others. Secondly, there was, and is, a government-led emphasis on
commercial exploitation of discoveries within the medical school.
----------------------------------------------------------------------------
----

Transfer Factor (TF)
A clinical trial of measles-virus specific transfer factor was planned in
order to determine whether there was benefit to children with regressive
autism and inflammatory bowel disease.
It is not known at this stage whether this therapy would work. The purpose
of the trial was to start to answer exactly this question as well as to
monitor the safety of TF in these children.
This was a treatment trial, not a vaccine trial.
A trial of TF was based upon an extensive scientific literature,
demonstrating safety and efficacy of TF in different diseases. I consulted
widely with experts in the UK and US on the history and scientific
background to TF both prior to and in the planning of the trial.
The protocol was extensively peer-reviewed with written endorsement from
experts in the UK and US. The trial protocol was submitted to, and
subsequently approved by, the Ethical Practices Committee of the Royal Free
Hampstead NHS Trust.
The trial protocol was approved by the participating physicians.
The trial was funded by charitable foundations after independent peer-review.
The trial was cancelled due, in part, to my departure from the Royal Free.

----------------------------------------------------------------------------
----

The Patent
A provisional patent filing was made for the use of measles virus-specific
TF in regressive autism and inflammatory bowel disease (Regressive Bowel
Disease; RBD).
The reference to the possible use of TF to protect children against measles
infection – the thrust of the Sunday Times’ conspiracy theory – was put in
as an afterthought in the patent. It was entirely speculative and never
pursued in any shape, manner or form.
The provisional patent filing was entirely speculative and was for a
possible therapy; as such, it had no bearing on the 1998 Lancet paper. It
constituted no potential conflict until the patent was awarded. When the
patent was later awarded, this fact was communicated directly to the Editor
of the Lancet in order that it might accompany a letter, written in
response to a paper by Taylor et al that claimed to find no evidence of a
link between MMR vaccine and autism. The editor did not consider the patent
disclosure of sufficient significance to publish it alongside my letter.
Since it was awarded, the patent has been disclosed in relevant
publications. The claims have since been abandoned.

----------------------------------------------------------------------------
----

Drs Nick Chadwick (NC) and Ian Bruce (IB): measles virus detection in
intestinal biopsies.
NC was employed as a post-graduate researcher in my laboratory, studying
for a PhD. He investigated various technologies for measles virus detection
using gene amplification. Due to problems within the laboratory with
contamination and the need for additional expertise, we collaborated with
IB at the University of Greenwich. IB and NC developed a technique that
increased the sensitivity of measles virus detection over standard
methodology from approximately 1 million viral copies in a reaction to
10,000 copies. In other words, even with the enhanced technique, the
technology could not detect this virus when present below 10,000 copies.

We published the fact that we could not detect measles virus in Crohn’s
disease using this technique. This publication went ahead on my
recommendation, despite some resistance to publishing negative data. I
considered that failure to publish negative data was inconsistent with good
scientific practice and proceeded to publication.

By the time we applied the viral detection technology to the intestinal
tissues of children with autism, new and more sensitive technology had come
to my attention. This includes the technique of TaqMan PCR and was
state-of-the-art technology being used by a few expert centres, including
that of Professor John O’Leary (JO’L), then at Cornell University in New
York. I went to New York to meet with JO’L. He presented evidence that his
technique could detect down to 2 viral copies, compared with NC’s 10,000.
The advantages were obvious and the possibility that NC’s results were
falsely negative (i.e. that the virus was present in the tissues but at
very low levels that NC’s technique could not detect) could now be
addressed by the new technology.

Using JO’L’s technology the virus was detected in controlled studies and
these results were published. They confirmed that our previous results were
falsely negative due to the limitation of the technique we were using.
TaqMan PCR, one of the techniques used by JO’L to detect measles virus in
the autistic children, is now the gold-standard and the technology used by
NC has been abandoned. On entirely scientific grounds I was proven correct
on this occasion. The facts stated above can be supported by
contemporaneous documentation.

AJW
--------------------------------------------------------
Sheri Nakken, R.N., MA, Classical Homeopath
http://www.nccn.net/~wwithin/vaccine.htm
--------------------------------------------------------------------
Sheri Nakken, R.N., MA, Classical Homeopath
Well Within & Earth Mysteries & Sacred Site Tours (worldwide)
Vaccination Information & Choice Network
http://www.nccn.net/~wwithin/vaccine.htm
http://www.nccn.net/~wwithin/homeo.htm
homeopathycures@tesco.net
ONLINE Introduction to Homeopathy Classes
ONLINE Introduction to Vaccine Dangers Classes
Voicemail US 530-740-0561 UK phone from US 011-44-1874-624-936